top of page
fundo-bcgene.jpeg

Research and Development of New Products

Competence in biotechnology, from
patent to product

Vaccines with higher protection against tuberculosis

Linhas_Branco_03.png

Pioneering in
recombinant BCG technology

A partnership with Instituto Butantan
Linhas_Branco_03.png

Recombinant technology applied to BCG strengthens and transforms its power to activate the immune system.

In the 1970s, it made history again by becoming the gold standard in the treatment of bladder cancer.

Bacillus Calmette-Guérin (BCG) entered medical history in 1921 as a vaccine against tuberculosis.

Bacillus Calmette-Guérin (BCG)

Linhas_azuis_01.png

A more efficient vaccine against tuberculosis

A more advanced treatment for bladder cancer

Scenario of human tuberculosis in the world

A dangerous
disease

 

Tuberculosis is among the Top-10 causes of death in the world. Brazil is among the countries with a high incidence of tuberculosis.

A demand
problem

​

Conventional BCG, traditionally used as a vaccine against tuberculosis, has an irregular global supply.

It was the most important cause of death from a single infectious agent (before the Sars-CoV-2 pandemic)

An efficiency
problem

​

Conventional BCG offers good protection against childhood tuberculosis but has reduced protection against pulmonary tuberculosis in adults.

Demanda

Linhas_azuis_02.png

1.7 million

deaths per year worldwide

4,500

deaths in Brazil,
200 new cases a day

Affects

mainly developing countries

Opportunities

BCG shows

reduced protection
in adults

150 million

doses is the estimated
world demand

10 million

doses is the estimated
demand for Brazil

Scenario of bovine tuberculosis in Brazil

Bovine tuberculosis has no vaccine or treatment.

​

The development of a veterinary vaccine against tuberculosis would have a major economic impact.

Demanda

Linhas_azuis_02.png

943 million

estimated global cattle herd

50 million

estimated number of infected individuals worldwide

U$ 3 billion

estimated global animal losses

234 million

estimated Brazilian herd in 2022

2.9 million

Infected individuals in Brazil in 2022

U$ 448 million

estimated annual loss in Brazil

Brazil

TUBERCULOSE – HOME
Linhas_azuis_02.png

Vaccine with greater protection

​

The new recombinant BCG vaccine for tuberculosis (rBCG-AdjTB – rBCG expressing an adjuvant) has shown greater protection against tuberculosis infection in experimental animals.

Recombinant BCG as improved vaccine against tuberculosis

grafico-tuberculose-ING-102.png
Linhas_azuis_01.png

Vaccine with greater protection

​

The new recombinant BCG vaccine for tuberculosis (rBCG-TB-A – rBCG expressing an adjuvant) has demonstrated longer-lasting protection against infection (up to 6 months) and reduced inflammation in experimental animals.

Recombinant BCG-TB-A: Long-lasting protection with reduced pathology

Grafico_ing-b.png
Linhas_azuis_01.png

Expected results

​

BCGene will carry out the product development stages in order to make the patent available for licensing to companies interested in producing and marketing the new rBCG tuberculosis vaccine.

Publications 

​

Proof-of-concept and mechanism-of-action studies of the new recombinant BCG vaccine against tuberculosis have been published in reputable international scientific journals.

​

The development process of the recombinant BCG vaccine against tuberculosis has been patented.

Linhas_azuis_02.png

Other products

IIn addition to the tuberculosis vaccine, we also use the recombinant BCG strategy (expressing an adjuvant) to develop a more effective treatment for bladder cancer.

 

rBCG for cancer

 

BCG modification has led to an improved treatment for bladder cancer. Different recombinant BCG strains in alternative formulations are being investigated for use against bladder cancer and lung cancer.

Contato

Contact

Thank you

Av. Brigadeiro Faria Lima,  3144,  conj. 31
 

Jardim Paulistano – São Paulo, SP, Brasil

 

01451-000

bottom of page